Full Press Release Details
Announces Pricing of $4.25 Million Public Offering
Inc. ("Aditxt") (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced
today the pricing of an underwritten public offering of 2,833,333 shares of its common stock at a public offering price of $1.50 per
share, for gross proceeds of $4.25 million, before deducting underwriting discounts and offering expenses.
plans to use a portion of the net proceeds of approximately $3.91 million from this offering to fund certain obligations under its previously
announced Transaction Agreement with AiPharma Global Holdings entered into on October 4, 2021.
Securities, LLC is acting as sole book-running manager for the offering.
offering of the common stock described above is being made pursuant to an effective "shelf" registration statement on Form
S-3 (File No. 333-257645), that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective
by the SEC on July 13, 2021, and the base prospectus contained therein. Such shares of common stock may be offered only by means of a
prospectus, including a prospectus supplement. A prospectus supplement and accompanying base prospectus related to the offering of common
stock will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement
and the accompanying base prospectus relating to the offering of common stock may be obtained, when available, by contacting Revere Securities,
LLC, 650 Fifth Avenue, 35th Floor, NY, NY 10019, jgiamichael@reveresecurities.com or (917) 710-5515.
press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction.
is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.
Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt's immune
reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with
an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit:
statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking
statements in this press release include, without limitation, the ability of the Company to close the offering. Forward-looking statements
include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among
other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's
ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results
may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those
risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as
well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities
and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
and Investor Relations Contact: